Table 6 Treatment selection: Proportion of therapies for post-menopausal ER+, HER2- metastatic BC patients used in first-line, second-line and third-line in the past 6 months – from physician survey (n = 103)

Oral hormonal therapy (e.g., tamoxifen, aromatase inhibitors)

51.91%

32.48

21.14%

22.40

12.55%

15.02

Other hormonal (e.g., fulvestrant)

11.68%

17.54

21.66%

23.76

16.32%

19.98

Chemotherapy

17.55%

18.43

25.58%

23.12

35.83%

27.27

Exemestane plus Everolimus

9.50%

14.44

22.38%

24.41

21.26%

23.71

Avastin plus chemotherapy

4.19%

9.73

4.91%

10.44

6.17%

14.42

Clinical trial

1.90%

6.16

2.34%

6.20

3.89%

9.27

Other

3.25%

-

2.00%

-

3.97%

-